Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Clinical trial NCT02103257 · UNKNOWN

Trial details

NCT number: NCT02103257
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

EGFR Positive Non-small Cell Lung Cancer Adenocarcinoma

Start date: 2014-03-01
Primary completion: 2016-03-01
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.